UNITED
      STATES


SECURITIES
      AND EXCHANGE COMMISSION


Washington,
      D.C. 20549





FORM
      10-Q





(Mark
      One)





þ
            Quarterly
                Report Under Section 13 or 15(d) of the Securities Exchange Act of
                1934




For
      the
      quarterly period ended March 31, 2008




o
            Transition
                Report Under Section 13 or 15(d) of the Securities Exchange Act of
                1934




For
      the
      transition period from  to





Commission
      File Number 000-03125





ADUROMED
      INDUSTRIES, INC.


(Exact
      Name of Registrant as Specified in Its Charter)





Delaware
            21-0661726(State
                or other Jurisdiction of
            (I.R.S.
                Employerincorporation
                or organization)
            Identification
                Number)




3
      Trowbridge Drive


Bethel,
      Connecticut 06801


(Address
      of Principal Executive offices)





(203)
      798-1080


(Issuer’s
      Telephone Number)





Indicate
      by check mark whether the registrant: (1) has filed all reports required to
      be
      filed by Section


13
      or
      15(d) of the Exchange Act during the preceding 12 months (or for such
      shorter


period
      that the registrant was required to file such reports), and (2) has
      been


subject
      to such filing requirements for the past 90 days.


Yes þ No o





Indicate
      by check mark whether the registrant is a large accelerated filer, an
      accelerated filer, or a non-accelerated filer. See definition of “accelerated
      filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check
      one):





Large
                Accelerated Filero
            
            Accelerated FileroNon-Accelerated Filero
            
            Smaller Reporting Companyþ





Indicate
      by check mark whether the registrant is a shell company (as defined
      in


Rule
      12b-2 of the Exchange Act). Yes o No þ





As
      of May
      12, 2008 21,965,306 shares of the issuer’s common stock (par value $0.0001 per
      share) were outstanding.





TABLE
      OF
      CONTENTS





PART
                I—FINANCIAL INFORMATIONPageItem
                1: Financial Statements
            F1 – F10Item
                2: Management's Discussion and Analysis or Plan of
                Operation
            3Item
                3: Quantitative and Qualitative disclosures about Market
                Risk
            6Item
                4: Controls and Procedures
            6PART
                II—OTHER INFORMATIONItem
                1: Legal Proceedings
            7Item1A:
                Risk Factors
            7Item
                2: Unregistered Sales of Equity Securities and Use of
                Proceeds
            7Item
                3: Defaults Upon Senior Securities
            7Item
                4: Submission of Matters to a Vote of Security Holders
            7Item
                5: Other Information
            7Item
                6: Exhibits
            8Signatures
            8





**PART
      I—FINANCIAL INFORMATION**





**Item
      1. Financial Statements**





INDEX
      TO
      CONSOLIDATED FINANCIAL STATEMENTS




PAGECONDENSED
                CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2008 AND DECEMBER 31, 2007
            F2UNAUDITED
                CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE QUARTERS ENDED
                MARCH 31, 2008 AND 2007
            F3UNAUDITED
                CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
              FOR
                THE QUARTERS ENDED MARCH 31,2008 AND 2007
            F4NOTES
                TO CONSOLIDATED FINANCIAL STATEMENTS
            F5


F-1


ADUROMED
      INDUSTRIES, INC.





CONDENSED
      CONSOLIDATED BALANCE SHEETS





March
                31,
            
            December
                31,2008
            
            2007(Unaudited)ASSETSCurrent
                assetsCash
            
            $
            225,035
            
            $
            212,215Accounts
                receivable (net of $11,418 allowance)
            
            
            200,716
            
            
            739,840Revenues
                in excess of billings
            
            
            61,448
            
            
            -Inventory
            
            
            581,966
            
            
            900,938Prepaid
                expenses
            
            
            55,350
            
            
            55,350Total
                current assets
            
            
            1,124,515
            
            
            1,908,343Property,
                plant and equipment, net
            
            
            328,820
            
            
            351,179Long
                term deposits
            
            
            17,988
            
            
            17,988Total
                assets
            
            $
            1,471,323
            
            $
            2,277,510LIABILITIES
                AND STOCKHOLDERS' DEFICITCurrent
                liabilitiesAccounts
                payable and accrued liabilities
            
            $
            523,048
            
            $
            517,402Deferred
                revenue
            
            
            219,783
            
            
            245,391Dividends
                payable
            
            
            969,013
            
            
            864,013Accrued
                liquidated damages
            
            
            602,000
            
            
            602,000Billings
                in excess of revenue
            
            
            753,776
            
            
            1,221,338Short
                term secured notes payable
            
            
            1,225,000
            
            
            1,225,000Convertible
                debt, face value $1,225,000, due June 27, 2008
            
            
            678,959
            
            
            28,892Short
                term notes payable related party
            
            
            300,000
            
            
            -Current
                portion of notes payable
            
            
            247,759
            
            
            197,756Total
                current liabilities
            
            
            5,519,338
            
            
            4,901,792Notes
                payable, less current portion
            
            
            63,894
            
            
            62,476Total
                liabilities
            
            
            5,583,232
            
            
            4,964,268Stockholders'
                deficitPreferred
                stock: $.0001 par value; 60,000,000 shares authorized; 22,043,862
                shares
                issued and outstanding
            
            
            2,204
            
            
            2,204Common
                stock: $.0001 par value; 200,000,000 shares authorized; 21,890,306
                and
                21,665,306 shares issued and outstanding
            
            
            2,189
            
            
            2,167Additional
                paid-in capital
            
            
            9,567,293
            
            
            9,363,671Accumulated
                deficit
            
            
            (13,683,595
            )
            
            (12,054,800
            )Total
                stockholders' deficit
            
            
            (4,111,909
            )
            
            (2,686,758
            )Total
                liabilities and stockholders' deficit
            
            $
            1,471,323
            
            $
            2,277,510


See
      Notes
      to Consolidated Financial Statements


F-2


ADUROMED
        INDUSTRIES, INC.
 
 CONDENSED
        CONSOLIDATED STATEMENTS OF OPERATIONS
 (Unaudited)


For
                the quarter endedMarch
                31,2008
            
            2007RevenuesContract
                revenues earned
            
            $
            523,484
            
            $
            581,591Sales
                and service revenues
            
            
            164,542
            
            
            189,015Total
                revenues
            
            
            688,026
            
            
            770,606Cost
                of sales
            
            
            475,598
            
            
            512,953Gross
                profit
            
            
            212,428
            
            
            257,653Operating
                expensesSalaries
                and wages
            
            
            370,841
            
            
            416,592General
                and administrative expenses
            
            
            565,547
            
            
            527,481Depreciation
                expense
            
            
            22,359
            
            
            23,200Total
                operating expenses
            
            
            958,747
            
            
            967,273Loss
                from operations
            
            
            (746,319
            )
            
            (709,620
            )Other
                income and expensesInterest
                income
            
            
            375
            
            
            8,869Interest
                expense
            
            
            (777,851
            )
            
            (45,927
            )Total
                other income and expenses
            
            
            (777,476
            )
            
            (37,058
            )Net
                loss before income taxes
            
            
            (1,523,795
            )
            
            (746,678
            )Provision
                for income tax benefit
            
            
            -
            
            
            -Net
                loss
            
            $
            (1,523,795
            )
            $
            (746,678
            )Basic
                and diluted net loss per common share
            
            $
            (0.07
            )
            $
            (0.04
            )Weighted
                average common shares outstanding
            
            
            21,736,185
            
            
            20,683,257


See
        Notes
        to Consolidated Financial Statements




F-3


ADUROMED
        INDUSTRIES, INC.
 
 CONDENSED
        CONSOLIDATED STATEMENTS OF CASH FLOWS
 (Unaudited)




Quarter
                    endedMarch
                    31,2008
                
                2007Cash
                    flows from operating activities:Net
                    loss
                
                $
                (1,523,795
                )
                $
                (746,678
                )Adjustments
                    to reconcile net loss tonet
                    cash used in operations:Warrants
                    and options issued for services
                
                
                203,644
                
                
                84,000Depreciation
                    expense
                
                
                22,359
                
                
                23,200Changes
                    in operating assets and liabilities:Accounts
                    receivable
                
                
                540,999
                
                
                (5,858
                )Revenues
                    in excess of billings
                
                
                (61,448
                )
                
                27,170Inventory
                
                
                318,972
                
                
                (294,688
                )Prepaid
                    interest
                
                
                -
                
                
                7,143Accounts
                    payable and accrued liabilities
                
                
                548,838
                
                
                (139,074
                )Deferred
                    revenue
                
                
                (25,608
                )
                
                86,860Billings
                    in excess of revenue
                
                
                (467,562
                )
                
                (21,307
                )Interest
                    on notes payable
                
                
                2,925
                
                
                2,925Dividends
                    payable
                
                
                105,000
                
                
                105,000Net
                    cash used in operating activities
                
                
                (335,676
                )
                
                (871,307
                )Cash
                    flows from investing activities:Purchase
                    of fixed assets
                
                
                -
                
                
                (10,430
                )Net
                    cash used in investing activities
                
                
                -
                
                
                (10,430
                )Cash
                    flows from financing activities:Repayments
                    of notes payable
                
                
                (1,504
                )
                
                (2,488
                )Issuance
                    of note payable
                
                
                300,000
                
                
                -Increase
                    in line of credit
                
                
                50,000
                
                
                -Net
                    cash provided by financing activities
                
                
                348,496
                
                
                (2,488
                )Increase
                    in cash and cash equivalents
                
                
                12,820
                
                
                (884,225
                )Cash
                    and cash equivalents, beginning of period
                
                
                212,215
                
                
                1,892,336Cash
                    and cash equivalents, end of period
                
                $
                225,035
                
                $
                1,008,111Supplemental
                    disclosures of cash flow information:Cash
                    paid for interest
                
                $
                38,712
                
                $
                1,016Supplemental
                    disclosures of noncash investing and financing activities:Accrual
                    of preferred stock dividents
                
                $
                105,000
                
                $
                105,000
  See
        Notes
        to Consolidated Financial Statements


F-4


ADUROMED
      INDUSTRIES INC





NOTES
      TO
      CONSOLIDATED FINANCIAL STATEMENTS


1.  BASIS
      OF
      PRESENTATION





The
      condensed consolidated balance sheets of Aduromed Industries Inc., and
      subsidiaries (“Aduromed”, the “Company”,“AII”) as of March 31, 2008 and December
      31, 2007, the condensed consolidated statements of operations for the three
      month period ended March 31, 2008 and 2007, and the condensed consolidated
      statements of cash flows for the three month period ended March 31, 2008 and
      2007 have been prepared by the Company without audit. In the opinion of
      management, the information contained herein reflects all adjustments necessary
      to make the presentation of the Company’s condensed financial position, results
      of operations and cash flows not misleading. All such adjustments are of a
      normal recurring nature.





The
      accompanying condensed consolidated financial statements do not contain all
      of
      the information and disclosures required by accounting principles generally
      accepted in the United States of America and should be read in conjunction
      with
      the consolidated financial statements and related notes included in the
      Company’s annual report on Form 10-K for the fiscal year ended December 31,
      2007, filed on March 31, 2008.





The
      accompanying consolidated financial statements have been prepared assuming
      that
      the Company will continue as a going concern, which contemplates the realization
      of assets and satisfaction of liabilities and commitments in the normal course
      of business. The Company has incurred substantial recurring losses, which raises
      substantial doubt about its ability to continue as a going concern. The
      consolidated financial statements do not include any adjustments that might
      result from the outcome of this uncertainty.





The
      Company has available cash and cash equivalents of approximately $225,035 at
      March
      31, 2008 which it intends to utilize for working capital purposes and to
      continue developing its business. To supplement its cash resources, the Company
      has been pursuing a number of alternative financing arrangements with various
      investment entities. We are currently looking to secure additional working
      capital to provide the necessary funds for us to execute our business plan
      through various sources, including bank facilities, bridge loans and equity
      offerings. However, we continue to incur significant operating losses and the
      resultant reduction of our cash position. We cannot assure that we will be
      able
      to obtain additional funding, and the lack thereof would have a material adverse
      impact on our business. Moreover, any equity funding could be substantially
      dilutive to existing stockholders. The aforementioned factors raise substantial
      doubt about our ability to continue as a going concern.


F-5


ADUROMED
      INDUSTRIES INC





NOTES
      TO
      CONSOLIDATED FINANCIAL STATEMENTS


2.  BUSINESS
      DESCRIPTION - ORGANIZATION





The
      Company designs, fabricates and installs systems to treat regulated medical
      waste on site. Its principal products are the Aduromed MedClean® series
      systems. AII through its subsidiary provides MedClean® systems
      to hospitals and other medical facilities as efficient, safe, cost-effective
      and
      legally-compliant solutions as alternatives to incineration or off-site hauling
      of untreated medical waste and to other types of alternative treatment
      technologies and methodologies.


F-6


ADUROMED
      INDUSTRIES INC





NOTES
      TO
      CONSOLIDATED FINANCIAL STATEMENTS


3.  SUMMARY
      OF SIGNIFICANT ACCOUNTING POLICIES





EARNINGS
      (LOSS) PER COMMON SHARE





The
      net
      earnings (loss) per common share are computed by dividing the net loss for
      the
      period by the weighted average number of shares outstanding for the period.
      Outstanding warrants and options for the quarter ending March 31, 2008 and
      2007
      amounting to 45,107,447 and
      40,773,639 respectively were not included in the calculation for net loss per common share
      because it would be antidilutive.





Outstanding
      Preferred A and B class of stock nor the common stock equivalents associated
      with the conversion feature for the year ending March 31, 2008 and 2007
      amounting to 22,043,862 for both periods of both classes of Preferred stock
      were
      not included in the calculation for net loss per common share as it would be
      antidilutive.





The
      numerator and denominator used in the basic and diluted earnings (loss) per
      share of common stock computations are presented in the following
      table:




For
                the quarter ended March 31,2008
            
            2007NUMERATOR
                FOR BASIC AND DILUTED EPS (LPS)Net
                loss per statement of operations
            
            $
            (1,523,795
            )
            $
            (746,678
            )Dividend
                payable to preferred stockholders
            
            
            (105,000
            )
            
            (105,000
            )Net
                loss to common stockholders
            
            $
            (1,628,795
            )
            $
            (851,678
            )DENOMINATOR
                FOR BASIC AND DILUTED EPS (LPS)Weighted
                average shares of common stock outstanding
            
            
            21,736,185
            
            
            20,683,257Basic
                and diluted EPS (LPS)
            
            $
            (0.07
            )
            $
            (0.04
            )





USE
      OF
      ESTIMATES





The
      preparation of the accompanying financial statements, in conformity with
      generally accepted accounting principles, requires management to make estimates
      and assumptions that affect the reported amounts of assets and liabilities,
      and
      disclosure of contingent assets and liabilities at the date of the financial
      statements, and the reported amounts of revenue and expenses during the
      reporting periods. Actual results could differ from those
      estimates.





CASH
      AND
      CASH EQUIVALENTS





The
      Company considers all highly liquid debt instruments purchased with an original
      maturity of three months or less to be cash equivalents.





The
      Company maintains cash deposits with financial institutions, which from time
      to
      time may exceed Federally insured limits. The Company has not experienced any
      losses and believes it is not exposed to any significant credit risk from cash.
      At March 31, 2008, the Company has cash balances on deposit in one account
      with
      a financial institution in excess of the Federally insured limits by a total
      of
      approximately $125,000.


F-7


ADUROMED
      INDUSTRIES INC





NOTES
      TO
      CONSOLIDATED FINANCIAL STATEMENTS


CONTROL
      BY PRINCIPAL STOCKHOLDERS





The
      directors, executive officers and their affiliates or related parties, own
      beneficially and in the aggregate, the majority of the voting power of the
      outstanding shares of the common stock of the Company. Accordingly, the
      directors, executive officers and their affiliates, if they voted their shares
      uniformly, would
      have the ability to control the approval of most corporate actions, including
      increasing the authorized capital stock of the Company and the dissolution,
      merger or sale of the Company's assets.





DEPENDENCE
      ON PRINCIPAL CUSTOMER





One
      principal customer, Aramark, represents a significant portion of our revenues.
      We recognized revenue of approximately $335,552 or 48% and $169,685 or 22%
      of
      total revenue from Aramark in the first quarter of 2008 and 2007, respectively.
      The loss of our principal customer would have a significant adverse impact
      on
      our business.





ACCOUNTS
      RECEIVABLE





The
      Company maintains an accounts receivable ledger to track amounts due from
      individual customers. The Company continuously monitors the creditworthiness
      of
      its customers and has established an allowance for amounts that may be
      uncollectible in the future based on current economic conditions, historical
      payments and specific customer related collection issues. The allowance for
      bad
      debts was $11,418 as of March 31, 2008 and December 31, 2007.





PROPERTY,
      PLANT AND EQUIPMENT





The
      Company has property, plant and equipment that consist of automobiles, computers
      and related accessories, and office furniture. The depreciation is calculated
      using the straight line method over the life of the property. All property
      has a
      useful life of 3 to 10 years. The following table summarizes these assets as
      of
      March 31, 2008 and December 31, 2007:


March
                31,
            
            December
                31,2008
            
            2007Vehicles
            
            
            41,338
            
            
            41,338Office
                Furniture
            
            
            164,525
            
            
            164,525Computers
                and Accessories
            
            
            175,485
            
            
            175,485Leasehold
                Improvements
            
            
            117,997
            
            
            117,997499,345
            
            
            499,345Accumulated
                Depreciation
            
            
            170,525
            
            
            148,166328,820
            
            
            351,179





INVENTORY





The
      Company maintains an inventory, which consists primarily of component parts,
      spare parts and disposable goods. The average cost method is utilized in valuing
      the inventory, and is stated at the lower of cost or market. The following
      table
      summarizes these assets as of March 31, 2008 and December 31,
      2007:


F-8


ADUROMED
      INDUSTRIES INC





NOTES
      TO
      CONSOLIDATED FINANCIAL STATEMENTS





March 31,
            
            December 31,2008
            
            2007Component
                & spare parts
            
            
            403,875
            
            
            742,310Consumables
            
            
            27,667
            
            
            29,384Advance
                payments
            
            
            150,424
            
            
            129,244Total
                inventory
            
            
            581,966
            
            
            900,938




REVENUE
      RECOGNITION





The
      Company recognizes revenues from fixed-price and modified fixed-price
      construction type contracts on the percentage-of-completion method, measured
      by
      the percentage of cost incurred to date to estimated total cost for each
      contract. That method is used because management considers total cost to be
      the
      best available measure of progress on the contracts. Because of inherent
      uncertainties in estimating costs, it is at least reasonably possible that
      the
      estimates used will change within the near term. The Company typically bills
      25%
      of the contract at signing, 50% upon delivery of components, and the final
      25%
      upon completion of installation and start-up.





Contract
      costs include all direct material and labor costs and those indirect costs
      related to contract performance. Selling, general and administrative costs
      are
      charged to expense as incurred. Provisions for estimated losses on uncompleted
      contracts are made in the period in which such losses are determined. Changes
      in
      job performance, job conditions, and estimated profitability may result in
      revisions to costs and income, which are recognized in the period in which
      the
      revisions are determined. Changes in estimated job profitability resulting
      from
      job performance, job conditions, contract penalty provisions, claims, change
      orders, and settlements, are accounted for as changes in estimates in the
      current period.





The
      Company provides a one year warranty on the systems it installs. The Company
      also obtains a one year warranty on the system components from the component
      manufacturer, thereby mitigating potential warranty costs. Accordingly, the
      Company has accrued no reserve for warranty. After the warranty term expires
      the
      Company offers a maintenance agreement of one or more years to the customer.
      The
      Customer is billed for, and pays for the maintenance agreement in advance.
      Revenues from such maintenance agreements are recognized ratably over the lives
      of the maintenance agreements, with the excess of the amount collected over
      the
      amount recognized as deferred revenue. At March 31, 2008 and December 31, 2007,
      the Company had $219,783 and $245,391, respectively in deferred revenue from
      maintenance agreements.





Revenues
      from the sale of accessories, repairs and replacement parts are recognized
      when
      the goods are shipped to the customer in accordance with a valid order
      agreement. The order agreement specifies delivery terms and pricing, and is
      considered to reasonably assure collection from the customer.





4.  CONTRACTS
      IN PROGRESS





The
      Company entered into construction type contracts to furnish and install its
      systems in hospitals. There were three outstanding contracts at March 31, 2008.
      The following table summarizes these outstanding contracts:





F-9


ADUROMED
        INDUSTRIES INC
 
 NOTES
        TO
        CONSOLIDATED FINANCIAL STATEMENTS


Contract
            
            Revenue
            
            Amounts
            
            Revenues in
            
            Billings in excessAmount
            
            Recognized
            
            Billed
            
            excess of Billings
            
            of RevenuesOutstanding
                contracts at March 31, 20081,327,930
            
            
            869,341
            
            
            1,327,930
            
            
            -
            
            
            458,589231,257
            
            
            12,447
            
            
            12,447
            
            
            -
            
            
            -483,596
            
            
            163,939
            
            
            120,899
            
            
            43,040
            
            
            -299,759
            
            
            64,875
            
            
            188,689
            
            
            -
            
            
            123,814559,594
            
            
            20,158
            
            
            191,531
            
            
            -
            
            
            171,373473,014
            
            
            176,079
            
            
            157,671
            
            
            18,408
            
            
            -61,448
            
            
            753,776Outstanding
                contracts at December 31, 20071,327,930
            
            
            683,593
            
            
            1,327,930
            
            
            -
            
            
            644,337483,117
            
            
            458,995
            
            
            483,117
            
            
            -
            
            
            24,122231,257
            
            
            12,447
            
            
            12,447
            
            
            -
            
            
            -483,596
            
            
            106,076
            
            
            120,899
            
            
            -
            
            
            14,823257,820
            
            
            -
            
            
            257,820
            
            
            -
            
            
            257,820282,948
            
            
            -
            
            
            94,316
            
            
            -
            
            
            94,316559,594
            
            
            5,611
            
            
            191,531
            
            
            -
            
            
            185,920-
            
            
            1,221,338




5.  SHORT
      TERM NOTES PAYABLE RELATED PARTY





On
      March
      17, 2008, the Company entered into a factoring agreement with a stockholder
      of
      the company whereby the Company received $300,000 secured by specific milestone
      billings and will expire June 16, 2008. The company agreed to pay interest
      at
      15% per annum. As further incentive the Company issued 600,000 warrants with
      an
      exercise price of $0.09. The
      estimated value of the warrants is added to paid-in-capital and amortized to
      interest expense over the live of the loan. The
      warrant agreement expires on March 16, 2013.





6.  NOTE
      PAYABLE





The
      Company has a note payable to a bank. The note is personally guaranteed by
      an
      officer of the Company, bears interest at the bank’s prime interest rate
      adjusted quarterly (7.25% at March 31, 2008 and 7.75% at December 31, 2007. In
      the
      quarter the Company borrowed an additional $50,000 on this line of credit.
      The
      balance of $100,000 is due in 2012.





7.  COMMON
      STOCK





In
      the
      quarter, 225,000
      shares of common stock were issued to a business advisor and consultant to
      the
      Company as part of his compensation package. The stocks were valued at $0.23
      per
      share for a total value of $51,750. The Company has a further obligation to
      issue 75,000 shares of common stock per month through August 22,
      2008.





8.  RECLASSIFICATION





We
      reclassified warrants amortization expenses in the first quarter of 2007 from
      General and Administrative expenses to interest expense to conform to the
      current period presentation. There is no effect on the net loss for the prior
      period.


F-10


**Item
      2. Management's Discussion and Analysis or Plan of
      Operation**





**Forward
      Looking Statements**





The
      Company is including the following cautionary statement in this Interim Report
      on Form 10-Q for any forward-looking statements made by, or on behalf of, the
      Company including its wholly-owned subsidiary Aduromed Corporation.
      Forward-looking statements include statements concerning plans, objectives,
      goals, strategies, future events or performance and underlying assumptions
      and
      other statements which are other than statements of historical facts. Certain
      statements contained herein are forward-looking statements and accordingly
      involve risks and uncertainties which could cause actual results or outcomes
      to
      differ materially from those expressed in the forward-looking statements. Our
      expectations, beliefs and projections are expressed in good faith and are
      believed by us to have a reasonable basis, including without limitation,
      management’s examination of historical operating trends, data contained in our
      records and other data available from third parties, but there can be no
      assurance that management’s expectation, beliefs or projections will result or
      be achieved or accomplished. In addition to other factors and matters discussed
      elsewhere herein, the following are important factors that, in our view, could
      cause actual results to differ materially from those discussed in the
      forward-looking statements: technological advances by our competitors, changes
      in health care reform, including reimbursement programs, changes to regulatory
      requirements relating to environmental approvals for the treatment of infectious
      medical waste, capital needs to fund any delays or extensions of development
      programs, delays in the manufacture of new and existing products by us or third
      party contractors, market acceptance of our products, the loss of any key
      employees, delays in obtaining federal, state or local regulatory clearance
      for
      new installations and operations, changes in governmental regulations,
      availability of capital on terms satisfactory to us and continuing good
      relations with Aramark Corporation. We are also subject to numerous Risk Factors
      relating to manufacturing, regulatory, financial resources and personnel as
      described in this Annual Report on Form 10-K. We disclaim any obligation to
      update any forward-looking statements to reflect events or circumstances after
      the date hereof.





**Results
      of Operations**





**Quarter
      Ended March** **31,
      2008 Compared to the Quarter Ended March 31, 2007**





*Net
      Revenue*





Total
      revenue for the quarter ended March 31, 2008 was $688,026 compared with $770,606
      for the same period in 2007, a reduction of $82,580 or 10.7%. Contract backlog
      as of March 31, 2008 was $2,431,008.





Revenues
      from our MedClean product for the current quarter were $523,484 and $581,591
      in
      the same quarter of 2007. In the quarter we worked on contracts previously
      awarded in prior years. We were awarded a new contract too late in the quarter
      to allow us to recognize revenue in the quarter.





Revenues
      derived from the sale of consumables, component parts and service contracts
      decreased by $24,473 or 12.9% to $164,542 from $189,015 in 2007. The decrease
      in
      revenue was attributable to the timing of orders for consumable products and
      service contracts from hospitals that have previously purchased our MedClean
      system compared to last year.





Orders
      for the MedClean system are contracted by purchase order and are billed in
      3
      increments. Typically, we bill our customers for 25% of the contact value at
      signing, 50% when the equipment is shipped to the customer and 25% upon
      completion of installation and start-up. Consumables and component parts are
      billed when shipped and service contracts are invoiced at the start of the
      service period and revenue is pro-rated over the life of the contract.


3


*Gross
      Profit*




The
      gross
      profit for the first quarter of 2008 was $212,428 (30.9% of total revenue)
      compared with a gross margin of $257,653 (33.4% of total revenue) for 2007,
      a
      decrease of $45,225. Gross profit was impacted by the reduction of revenue
      and
      product mix.




The
      components of costs of revenues for products include direct materials, shipping
      and rigging costs and contract labor primarily used to install, repair and
      maintain our equipment.




*Operating
      Expenses*




Total
      operating expenses for the first quarter of 2008 was $958,747 compared with
      $967,273 for the same period in 2007, a decrease of $8,526  The decrease
      included staff reductions of $45,751, savings on travel and marketing expenses
      of $53,895 offset by an increase in business consulting of $86,359. All other
      operating expenses increased $4,761 net.




*Interest
      (Income) Expense*




Interest
      income for the quarter was $375 compared with $8,869 of interest income in
      the
      same period of 2007 on reduced cash balances available for investment. The
      Company invests its excess cash in a money market account. As of March 31,
      2008
      the interest rate was 3.25%.




Interest
      expense and amortization for the current quarter was $777,851 compared with
      $45,927 in the same period of 2007. Interest expense for the first quarter
      of
      2008 was $38,438 on increased borrowings totaling $1,575,000 of principal In
      the
      first quarter of 2008 we recognized non-cash amortization expense for warrants
      issued amounting to $734,339 compared to $41,397 in the first quarter of 2007. In
      June
      of 2007, the Company borrowed $1,275,000 at a rate of 12% per annum due on
      December 27, 2007. The loan was extended and is due on June 27, 2008. In
      consideration of the extension the lenders received 2,450,000 of additional
      warrants which will expire in five years and, have an exercise price equal
      to
      the exercise price of warrants issued in the Company’s next financing involving
      the issuance of the Company’s common stock or securities convertible into such
      common stock with proceeds of $2,000,000 or more. As additional consideration
      for agreeing to such extension these holders were given the right to convert
      the
      principal amount of their secured notes into common stock of the Company prior
      to the Company’s next Qualified Financing at a conversion price equal to
      one-half of the closing market price of such common stock on the day of
      conversion. The beneficial conversion feature was calculated at its intrinsic
      value on December 27, 2007 .




*Net
      loss*




Net
      loss
      for the current quarter was $(1,523,795) compared to a net loss for the same
      period in 2007 of $(746,678).




*Net
      Loss Attributable to Common Stockholders*




Net
      loss
      attributable to common stockholders for this period of 2008 was $(1,628,795)
      or
      $(0.07) cents per share (basic and diluted), compared to a net loss of
      $(851,678) or $(0.04) cents per share (basic and diluted) for the same period
      in
      2007.




During
      the quarter, the Company accrued $105,000 in dividends with an interest rate
      of
      6% on $7,000,000, the total value received for both series A and B preferred
      stock.


4







Financial
      Condition





*Liquidity
      and Capital Resources*





The
      Company’s cash on hand and working capital as of March 31, 2007 and December 31,
      2007 are as follows:





March 31,
            
            December 31,2008
            
            2007Cash
                on hand
            
            $
            225,035
            
            $
            212,215Working
                capital
            
            $
            (4,394,823
            )
            $
            (2,993,449
            )





The
      Company has purchased no new fixed assets in the current quarter. Under current
      conditions the Company anticipates purchasing approximately $25,000 in
      additional fixed assets in 2008.




Net
      cash
      used in operating activities totaled $338,601 for the quarter ended March 31,
      2008





Our
      accounts receivable balance may have dramatic swings from one period to
      another depending upon the timing and the amount of milestone billings
      included in the balance at the end of any accounting period. There are
      three milestone billings representing a percentage of the contract value
      for each installment and our payment terms are ``upon receipt''. Receivable
      balances are typically paid within 15 days of the invoice date. Billings
      for maintenance contracts and consumables are due within 45 days and are
      more numerous but much smaller in value than milestone billings. We review
      our outstanding receivable balances on a regular basis to ensure that the
      allowance for bad debt is adequate.   Due to the varying nature in the
      timing and amounts of the receivable balances as noted above, the change in
      the allowance for doubtful account will not necessarily correlate with the
      increase or decrease in the accounts receivable balance.





Our
      inventory balance may have dramatic swings from one period to another
      depending upon the expected installation date of our MedClean systems and our
      accounts payable balances can have similar swings depending on payment
      terms and any volume purchases or discounts we may take advantage of from
      time to time. During the first quarter of 2008, the Company reduced its
      inventory on hand by $318,972 to $581,966. The accounts payable balance as
      of March 31, 2008 was $523,048.





On
      March
      17, 2008, the Company entered into a factoring agreement with a stockholder
      of
      the company whereby the Company received $300,000 secured by specific milestone
      billings and will expires June 16, 2008. The company agreed to pay interest
      at
      15% per annum. As further incentive the Company issued 600,000 warrants with
      an
      exercise price of $0.09. The warrant agreement expires on March 16, 2013.





In
      the
      quarter the Company borrowed an additional $50,000 on a $100,000 line of credit
      it has with a bank. The balance of $100,000 is due in 2012.


5





To
      supplement its cash resources, the Company has been pursuing a number of
      alternative financing arrangements with various investment entities. We are
      currently looking to secure additional working capital to provide the necessary
      funds for us to execute our business plan through various sources, including
      bank facilities, bridge loans and equity offerings. However, we continue to
      incur significant operating losses and the resultant reduction of our cash
      position. We cannot assure that we will be able to obtain additional funding,
      and the lack thereof would have a material adverse impact on our business.
      Moreover, any equity funding could be substantially dilutive to existing
      stockholders. The aforementioned factors raise substantial doubt about our
      ability to continue as a going concern.





AII
      has
      an obligation to pay dividends on the value of its preferred stock at a rate
      of
      6%. To date we have accrued $969,013 in dividends payable.





AII
      has
      accrued $602,000 in liquated damages payable to its Preferred stockholders.





The
      Company with the consent of its Preferred stockholders can pay these obligations
      in kind with common stock based upon certain formulas contained in the
      stockholders purchase agreement.





**Item
      3. Quantitative and Qualitative Disclosures about Market Risk**





Not
      required ****





**Item
      4. Controls and Procedures**





As
      of the
      three month period ended March 31, 2008 covered by this report, the Company
      carried out, under the supervision and with the participation of the Company's
      management, including its Chief Executive Officer and Chief Financial Officer,
      an evaluation of the effectiveness of the design and operation of the Company's
      disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e)
      under the Securities Exchange Act of 1934). Based upon and as of the date of
      that evaluation, the Chief Executive Officer and Chief Financial Officer
      concluded that the design and operation of these disclosure controls and
      procedures are effective.


6





**PART
      II—OTHER INFORMATION**





**Item
      1: Legal Proceedings** .





The
      Company has no pending legal proceedings. From time to time, it may be involved
      in various claims, lawsuits or disputes with third parties, and actions
      involving allegations of breach of contract incidental to the normal business
      operations of Aduromed’s business.





**Item
      1A: Risk Factors.**





There
      have been no material changes from the risk factors previously disclosed in
      the
      Company’s Annual Report on Form 10-K for the fiscal year ended December 31,
      2007.





**Item
      2. Unregistered Sales of Equity Securities and Use of
      Proceeds**




Pursuant
      to
      an agreement dated August 23, 2007, the Company engaged Mr. Joseph Esposito
      as a
      corporate and business development advisor. During January, February and March
      2008 the Company issued a total of 225,000 shares of the Company’s common stock
      to Mr. Esposito as part of Mr. Esposito’s compensation package as an advisor to
      the Company. The Company did not receive any cash proceeds from these
      issuances.





Effective
        March 17, 2008, in partial consideration for their participation in an accounts
        receivable purchase from the Company, the Company issued to existing individual
        shareholders warrants for the purchase of 600,000 shares of the Company’s common
        stock. These are five year warrants and have an exercise price of $0.09 per
        share, the closing marker process for the common stock as of March 17,
        2008





The
      offer
      and sale of these securities was claimed exempt from the registration provisions
      of the Securities Act by reason of Section 4(2) thereof and Regulation D
      thereunder. Management made its determination of the availability of such
      exemption based upon the facts and circumstances surrounding the transactions,
      including the representations and warranties made by the investors and the
      fact
      that restrictive legends were placed on the notes and the warrants.




There
      were no other unregistered sales of the Company’s equity securities during the
      quarter ended March 31, 2008.





**Item
      3. Defaults upon Senior Securities.**





There
      has
      been no default in the payment of principal, interest, sinking or purchase
      fund
      installment, or any other material default not cured with in 30 days, with
      respect to any indebtedness of the Company exceeding 5 percent of its total
      assets.





**Item
      4. Submission of Matters to a Vote of Security Holders.**





No
      matters have been submitted to security holders of the Company during the period
      covered by this report. ****  ****




**Item
      5: Other Information**





None


7


**I** **tem
      6. Exhibits**





NUMBER
            
            DESCRIPTION
                OF EXHIBIT4.1
            
            Form
                of Series A Warrant (incorporated by reference to Exhibit 4.1 to
                Registrant’s Form 10-KSB, filed April 21, 2006).4.2
            
            Form
                of Series B Warrant (incorporated by reference to Exhibit 4.2 to
                Registrant’s Form 10-KSB, filed April 21, 2006).4.3
            
            Certificate
                of Designations of Series A Preferred Stock (incorporated by reference
                to
                Exhibit 4.4 to Registrant’s Form 10-KSB, filed April 21,
                2006).4.4
            
            Certificate
                of Designations of Series B Preferred Stock (incorporated by reference
                to
                Exhibit 4.5 to Registrant’s Form 10-KSB, filed April 21,
                2006).4.5
            
            Loan
                and Security Agreement, dated as of June 27, 2007, by and among Aduromed
                Industries, Inc., Aduromed Corporation and the investors named on
                the
                signature pages thereto(incorporated
                by reference to Exhibit 4.01 to Registrant’s Form 8-K, filed July 2,
                2007).4.6
            
            Form
                of Secured Promissory Note(incorporated
                by reference to Exhibit 4.02 to Registrant’s Form 8-K, filed July 2,
                2007).4.7
            
            Form
                of Common Stock Purchase Warrant(incorporated
                by reference to Exhibit 4.03 to Registrant’s Form 8-K, filed July 2,
                2007).4.8
            
            Subsidiary
                Guarantee, dated as of June 27, 2007, from Aduromed Corporation in
                favor
                of the investors named on the signature pages of the Loan and Security
                Agreement(incorporated
                by reference to Exhibit 4.04 to Registrant’s Form 8-K, filed July 2,
                2007).31.1*
            
            Certification
                by the Principal Executive Officer of Registrant pursuant to Section
                302
                of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule
                15d-14(a)).31.2*
            
            Certification
                by the Principal Financial Officer of Registrant pursuant to Section
                302
                of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule
                15d-14(a)).32.1*
            
            Certification
                by the Chief Executive Officer pursuant to 18 U.S.C. 1350 as adopted
                pursuant to Section 906 of the Sarbanes-Oxley Act of
                2002.32.2*
            
            Certification
                by the Chief Financial Officer pursuant to 18 U.S.C. 1350 as adopted
                pursuant to Section 906 of the Sarbanes-Oxley Act of
                2002.





*
      Filed
      herein.





SIGNATURES





In
      accordance with the requirements of the Exchange Act, the registrant caused
      this
      report to be signed on its behalf by the undersigned, thereunto duly
      authorized.





Registrant





ADUROMED
      INDUSTRIES, INC.





Date:
                May 14, 2008
            
            Date:
                May 14, 2008By:
            /s/
                Damien R. Tanaka
            
            By:
            /s/
                Kevin T. DunphyDamien
                R. Tanaka,
            
            Kevin
                T. DunphyChairman
                of the Board, President
              and
                Chief Executive Officer
            
            Treasurer
                and
              and
                Chief Financial Officer(Principal
                Executive Officer)
            
            (Principal
                Financial and Accounting
                Officer)


8